Oncolytics Biotech Secures New U.S. Patent for Pelareorep Manufacturing
Oncolytics Biotech Inc. announced it has secured a new U.S. patent from the USPTO, broadly protecting its proprietary manufacturing process for pelareorep. This patent is expected to provide intellectual property protection into 2044, supporting the company's ability to produce pelareorep at commercial scale. Additionally, a previously filed method-of-use patent application remains under review, potentially extending protection into 2046, and further patent filings are planned for 2026 to strengthen the IP portfolio.
Key Highlights
- Oncolytics Biotech secured a new U.S. patent for its proprietary pelareorep manufacturing process.
- The newly issued patent is expected to provide intellectual property protection into 2044.
- A previously filed method-of-use patent application for pelareorep is under review, potentially protecting into 2046.
- The company plans further patent applications in 2026 to expand pelareorep's intellectual property estate.
- The patent strengthens protection for commercial-scale production of pelareorep.
Price Impact
More from ONCY
Oncolytics Biotech Appoints COO John McAdory, Adds Stephen Glover to Board
Oncolytics Appoints Steve Glover to Board, Promotes John McAdory to COO
Oncolytics Biotech Announces Positive Preclinical Data for Pelareorep